A Phase I Study of Radiation Therapy to Relieve Symptoms in Patients with Advanced Non-Small Cell Lung Cancer

Share
Print

Full Title

PROMISE 006: A Phase I Study of up to 3 cycles of Cyclical Hypofractionated Palliative Radiation (Quad Shot) for Lung Tumors in Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC)

Purpose

Researchers are doing this study to find out whether it is safe to give a treatment called Quad Shot radiation therapy to relieve symptoms in people with advanced non-small cell lung cancer (NSCLC) who will also be receiving chemotherapy and/or immunotherapy (“systemic therapy”). The Quad Shot treatment schedule reduces the number of days needed to deliver the radiation treatments, which may be less disruptive to systemic therapy schedules. Patients will receive either one, two, or three cycles of Quad Shot therapy.

Radiation therapy is frequently used to relieve symptoms in patients with advanced or metastatic cancers. About 75 percent of patients with advanced NSCLC receive such “palliative” radiation therapy as part of their care. It is hoped that Quad Shot radiation treatments can relieve the symptoms of advanced NSCLC while causing few or mild side effects.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have stage IV NSCLC and be planning to receive chemotherapy and/or immunotherapy for their cancer.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact the office of Dr. Annemarie Shepherd at 908-542-3430.

Protocol

20-148

Phase

I

Disease Status

Newly Diagnosed & Relapsed/Refractory

Co-Investigators